Trevena Announces Initiation of OLINVYK® Respiratory Physiology Study Including Elderly / Obese Subjects
July 07, 2021 07:00 ET
|
Trevena Inc.
-- Study is evaluating the role of age and weight in a comparative analysis of the effect of OLINVYK and morphine on respiratory function Led by world-renowned research group, utilizing an...
Trevena Announces Presentations of OLINVYK® Health Economic Models at ISPOR 2021
May 19, 2021 07:00 ET
|
Trevena Inc.
-- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care -- CHESTERBROOK, Pa., May 19, 2021 (GLOBE NEWSWIRE) --...
Trevena Announces Presentation of OLINVYK® Respiratory Safety Data in High-Risk Patients at the 46th Annual ASRA Meeting
May 12, 2021 07:00 ET
|
Trevena Inc.
-- Elderly and obese patients receiving OLINVYK are not at increased risk for respiratory depression, compared to younger and non-obese patients, based on exploratory analysis -- CHESTERBROOK, Pa.,...
Trevena Reports First Quarter 2021 Results
May 06, 2021 07:00 ET
|
Trevena Inc.
-- Company reaffirms YE target of 100 formulary approvals for OLINVYK® Announces new OLINVYK clinical outcomes study to further examine potential benefit on respiratory, GI, and...
Trevena, Inc. Announces Presentations of OLINVYK™ Health Economic Models at AMCP 2021 Annual Meeting
April 15, 2021 07:30 ET
|
Trevena Inc.
-- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care -- CHESTERBROOK, Pa., April 15, 2021 (GLOBE NEWSWIRE) --...
Trevena, Inc. Reports Fourth Quarter and Full Year 2020 Results
March 09, 2021 07:00 ET
|
Trevena Inc.
-- OLINVYK™ approved in U.S.; customer-facing teams now fully deployed Primary study completion for TRV027 in COVID-19 patients expected in 1H 2021 IND for TRV045 (S1P1 receptor modulator) on track...
Trevena to Release Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021
March 05, 2021 07:00 ET
|
Trevena Inc.
-- Company to host conference call on March 9th, 2021, at 8:00 a.m. ET -- CHESTERBROOK, Pa., March 05, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused...
Trevena, Inc. Announces Publication Highlighting OLINVYK™ Respiratory Safety Data in High-Risk Patients in Pain & Therapy
January 28, 2021 07:00 ET
|
Trevena Inc.
-- Low incidence of respiratory depression observed with OLINVYK (oliceridine) injection regardless of age or body mass index, in exploratory analysis -- CHESTERBROOK, Pa., Jan. 28, 2021 (GLOBE...
Trevena, Inc. Provides Update on Commercial Launch Activities for OLINVYK™ and Announces Anticipated Pipeline Catalysts
January 06, 2021 07:00 ET
|
Trevena Inc.
-- Build-out of customer-facing team on track for this quarter OLINVYK comprehensive product dossier / health economic model now available to facilitate formulary reviews -- CHESTERBROOK, Pa.,...
Trevena, Inc. Announces DEA Scheduling of OLINVYK™ (oliceridine) injection
October 30, 2020 07:44 ET
|
Trevena Inc.
-- OLINVYK commercial supply on track and available in November Company funded through Q4 2022, including OLINVYK commercialization -- Company to host conference call at 8:30 a.m. ET on Monday,...